381 related articles for article (PubMed ID: 21850390)
41. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
Avilés A; Neri N; Castañeda C; Talavera A; Huerta-Guzmán J; González M
Med Oncol; 2002; 19(1):55-8. PubMed ID: 12025891
[TBL] [Abstract][Full Text] [Related]
42. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
[TBL] [Abstract][Full Text] [Related]
43. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
[TBL] [Abstract][Full Text] [Related]
44. Frequency and severity of neutropenia in diffuse large B-cell non Hodgkin's lymphoma after first cycle of chemotherapy comprising cyclophosphamide, doxorubicin, vincristine with prednisolone.
Nadeem M; Idrees M; Khattak J; Hussain I; Amin Z; Arif S; Zeeshan M; Hussain M
J Ayub Med Coll Abbottabad; 2011; 23(1):80-3. PubMed ID: 22830154
[TBL] [Abstract][Full Text] [Related]
45. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.
Falandry C; Brain E; Bonnefoy M; Mefti F; Jovenin N; Rigal O; Guillem O; El Kouri C; Uwer L; Abadie-Lacourtoisie S; Cretin J; Jacquin JP; Paraiso D; Freyer G
Eur J Cancer; 2013 Sep; 49(13):2806-14. PubMed ID: 23735702
[TBL] [Abstract][Full Text] [Related]
46. The efficacy and cardiac toxicity of different-dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma.
Li L; Chen R; Zhou D; Sun J; Wang L; Zhu L; Shen H; Xie W; Ye X
Cancer Med; 2023 Feb; 12(4):4184-4194. PubMed ID: 36200320
[TBL] [Abstract][Full Text] [Related]
47. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
[TBL] [Abstract][Full Text] [Related]
48. [Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
Li ZH; Xing MT; Zhang YP; Wang Y; Zhan XR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):744-8. PubMed ID: 27342502
[TBL] [Abstract][Full Text] [Related]
49. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
50. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma.
Zaja F; Tomadini V; Zaccaria A; Lenoci M; Battista M; Molinari AL; Fabbri A; Battista R; Cabras MG; Gallamini A; Fanin R
Leuk Lymphoma; 2006 Oct; 47(10):2174-80. PubMed ID: 17071492
[TBL] [Abstract][Full Text] [Related]
51. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer.
Rom J; Bechstein S; Domschke C; Golatta M; Mayer C; Heil J; Thum J; Smetanay K; Windemuth-Kieselbach C; Wallwiener M; Marme F; Schuetz F; Sohn C; Schneeweiss A
Anticancer Drugs; 2014 Feb; 25(2):219-24. PubMed ID: 24247203
[TBL] [Abstract][Full Text] [Related]
53. Fertility status among women treated for aggressive non-Hodgkin's lymphoma.
Elis A; Tevet A; Yerushalmi R; Blickstein D; Bairy O; Dann EJ; Blumenfeld Z; Abraham A; Manor Y; Shpilberg O; Lishner M
Leuk Lymphoma; 2006 Apr; 47(4):623-7. PubMed ID: 16690520
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients.
Liu W; Yang M; Ping L; Xie Y; Wang X; Zhu J; Song Y
Cardiovasc Toxicol; 2021 Jan; 21(1):12-16. PubMed ID: 32683546
[TBL] [Abstract][Full Text] [Related]
55. [A phase Ⅰ dose-escalating trial of pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine and prednisone for aggressive non-Hodgkin lymphoma].
Shen WN; Ji DM; Xue K; Zhang QL; Lyu FF; Hong XN; Cao JN; Guo Y
Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1044-1048. PubMed ID: 28088967
[TBL] [Abstract][Full Text] [Related]
56. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
[TBL] [Abstract][Full Text] [Related]
57. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi.
Luminari S; Viel E; Ferreri AJM; Zaja F; Chimienti E; Musuraca G; Tucci A; Balzarotti M; Tani M; Salvi F; Pesce EA; Ferrari A; Liberati AM; Spadea A; Marino D; Bruno-Ventre M; Volpetti S; Bottelli C; Ravaioli E; Merli F; Spina M
Hematol Oncol; 2018 Feb; 36(1):68-75. PubMed ID: 28524259
[TBL] [Abstract][Full Text] [Related]
58. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study.
Jurczak W; Szmit S; Sobociński M; Machaczka M; Drozd-Sokołowska J; Joks M; Dzietczenia J; Wróbel T; Kumiega B; Zaucha JM; Knopińska-Posłuszny W; Spychałowicz W; Prochwicz A; Drohomirecka A; Skotnicki AB
Int J Cardiol; 2013 Oct; 168(6):5212-7. PubMed ID: 23998543
[TBL] [Abstract][Full Text] [Related]
59. High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
Peterson BA; Johnson J; Shipp MA; Barcos M; Gockerman JP; Canellos GP;
Leuk Lymphoma; 2007 May; 48(5):870-80. PubMed ID: 17487729
[TBL] [Abstract][Full Text] [Related]
60. [Non-Hodgkin's lymphoma: a new less toxic treatment doubles the prognosis].
Sabourin G
Perspect Infirm; 2012; 9(6):60. PubMed ID: 23234232
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
